147 related articles for article (PubMed ID: 38329745)
1. Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial.
Zhang S; Yin Y; Xiong H; Wang J; Liu H; Lu J; Zhang Q; Zhang L; Zhong J; Nie J; Lei K; Wang H; Yang S; Yao H; Wu H; Yu D; Ji X; Zhang H; Wu F; Xie W; Li W; Yao W; Zhong D; Sun H; Sun T; Guo Z; Wang R; Guo Y; Yu Z; Li D; Jin H; Song H; Chen X; Ma W; Hu Z; Liu D; Guo Y; Tang J; Jiang Z
JAMA Oncol; 2024 Apr; 10(4):448-455. PubMed ID: 38329745
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.
Li H; Huang Y; Chen Z; Zeng A; Zhang H; Yu Y; Wei S; Li Q; Wang X; Wang X; Wang X; Yang R; Dai X; Bi M; Sun T; Zhang Q; Han C; Li Y; Kang X; Liu Y; Zhang L
BioDrugs; 2023 Mar; 37(2):259-269. PubMed ID: 36802320
[TBL] [Abstract][Full Text] [Related]
3. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
Hou J; Hu Z; Xu W; Di Y; Song C; Wu F; Liu J; Guo Y
Int Immunopharmacol; 2022 Jun; 107():108666. PubMed ID: 35286913
[TBL] [Abstract][Full Text] [Related]
4. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
6. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman RE; Paterson AH; Gao GM; Kinsey AC; Peterson MC; Jun S
Clin Cancer Res; 2008 Oct; 14(20):6690-6. PubMed ID: 18927312
[TBL] [Abstract][Full Text] [Related]
7. Denosumab dose selection for patients with bone metastases from solid tumors.
Doshi S; Sutjandra L; Zheng J; Sohn W; Peterson M; Jang G; Chow AT; Pérez-Ruixo JJ
Clin Cancer Res; 2012 May; 18(9):2648-57. PubMed ID: 22394983
[TBL] [Abstract][Full Text] [Related]
8. Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial.
Singh I; Jose V; Patel R; Arora S
Indian J Pharmacol; 2021; 53(1):6-12. PubMed ID: 33975993
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
[TBL] [Abstract][Full Text] [Related]
10. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
Woo SJ; Bradvica M; Vajas A; Sagong M; Ernest J; Studnicka J; Veith M; Wylegala E; Patel S; Yun C; Orski M; Astakhov S; Tóth-Molnár E; Csutak A; Enyedi L; Kim T; Oh I; Jang H; Sadda SR
JAMA Ophthalmol; 2023 Jul; 141(7):668-676. PubMed ID: 37289448
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
[TBL] [Abstract][Full Text] [Related]
15. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
16. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
Leng X; Leszczyński P; Jeka S; Liu SY; Liu H; Miakisz M; Gu J; Kilasonia L; Stanislavchuk M; Yang X; Zhou Y; Dong Q; Rezk M; Mitroiu M; Addison J; Zeng X
Lancet Rheumatol; 2024 Jan; 6(1):e40-e50. PubMed ID: 38258678
[TBL] [Abstract][Full Text] [Related]
17. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Henry D; Vadhan-Raj S; Hirsh V; von Moos R; Hungria V; Costa L; Woll PJ; Scagliotti G; Smith G; Feng A; Jun S; Dansey R; Yeh H
Support Care Cancer; 2014 Mar; 22(3):679-87. PubMed ID: 24162260
[TBL] [Abstract][Full Text] [Related]
18. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
Smith MR; Saad F; Coleman R; Shore N; Fizazi K; Tombal B; Miller K; Sieber P; Karsh L; Damião R; Tammela TL; Egerdie B; Van Poppel H; Chin J; Morote J; Gómez-Veiga F; Borkowski T; Ye Z; Kupic A; Dansey R; Goessl C
Lancet; 2012 Jan; 379(9810):39-46. PubMed ID: 22093187
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
Jamshidi A; Vojdanian M; Soroush M; Akbarian M; Aghaei M; Hajiabbasi A; Mirfeizi Z; Khabbazi A; Alishiri G; Haghighi A; Salimzadeh A; Karimzadeh H; Shirani F; Fard MRH; Nazarinia M; Soroosh S; Anjidani N; Gharibdoost F
Arthritis Res Ther; 2022 Jun; 24(1):161. PubMed ID: 35773713
[TBL] [Abstract][Full Text] [Related]
20. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
Lee HA; Kim S; Seo H; Kim S
Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
